CD274 and breast cancer: Additionally, other phase II clinical trials are ongoing to assess the efficacy of the triple combination palbociclib plus ET and avelumab (anti-PD-L1) in HR+/HER2− BC patients with early-stage (ImmunoADAPT, NCT03573648) [237] or advanced (PACE, NCT03147287) [238,239] BC disease.